[ad_1]
However, the situation in the media market is constantly changing: if you want to support quality business journalism and want to be part of the Portfolio community, subscribe to Portfolio Signature articles. Know more
The announcement Saturday afternoon from the University of Oxford said that testing of the experimental vaccine, scientifically named ChAdOx1 nCoV-19, will continue at all UK testing program sites. According to the university, so far 18,000 participants have received the vaccine worldwide, and vaccine trials of this magnitude are always expected to cause health problems in some test subjects. According to the statement, all such cases must be carefully scrutinized to judge the safety of the program.
According to the university, the independent background investigation into the case has been completed and the UK testing program is being relaunched on the recommendation of the investigating body and the British Medicines Authority (MHRA).
The University of Oxford has stated that, for data protection reasons, it cannot provide details of the test subject’s disease in question. The information also does not cover when testing will resume in the UK. Unconfirmed press reports indicate that the affected participant in the test program developed symptoms of viral inflammation of the spinal cord.
The coronavirus vaccine, considered promising in professional circles, was developed by scientists at the University of Oxford and the university has agreed with AstraZeneca on its production and distribution should the coronavirus vaccine be successful in human trials. AstraZeneca CEO Pascal Soriot told BBC television a few weeks ago that the UK government had commissioned the company to produce 100 million units of the vaccine if the test program was successful.
Cover image: Getty Images
[ad_2]
